Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type (Hereditary Transthyretin Amyloidosis (hATTR), Wild Type Transthyretin Amyloidosis (wtATTR)), By Drug Type (Transthyretin Stabilizers, Nonsteroidal Anti-Inflammatory Drugs (NSAID), RNAi Therapy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Oct 2023

Code : CMI4321

Pages :160

Formats :

Excel and PDF

Industry : Pharmaceutical

Regional Analysis

Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market- Regional Analysis

North America is expected to dominate the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2023. Multiple factors contributes to the region's leading position such as, high concentration of key market players, high healthcare expenditure etc. For instance, in March 2023, according to data published by American Medical Association, the U.S. health expenditure was 18.3% of GDP in 2021, one of the highest in the world. This high expenditure ensures widespread insurance coverage and access to innovative treatments of ATTR-CM.
Europe is also expected to emerge as the fastest growing region for ATTR-CM treatment. Aging population across major European Union (EU) nations implies a growing patient pool who are susceptible to age-related conditions like ATTR amyloidosis over time. According to the data published by Eurostat in February 2023, more than one fifth (21.1 %) of the EU population was aged 65 and above in 2022.

Among type, hereditary transthyretin amyloidosis (hATTR) segment is dominant in Europe ATTR-CM treatment market due to favorable regulations and increasing focus on orphan drugs in the EU that promotes research and development of innovative therapies for rare diseases. The European Commission launched the " EU Action on Rare Diseases" in February 2023, committing to improve diagnosis, care and treatment for rare disease patients across EU member states. Such initiatives are encouraging more pharmaceutical players to direct their research efforts towards ATTR-CM and other orphan indications in Europe.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa